Advanced Viral Research Corp. to Initiate Phase II Trial in Cancer Patients
Wednesday September 5, 6:00 am ET
YONKERS, N.Y.--(BUSINESS WIRE)--Advanced Viral Research Corp. (OTCBB:ADVR - News), a research based biopharmaceutical company dedicated to anti-cancer drug discovery and development, announced today plans to initiate a Phase II clinical trial to evaluate the effectiveness of its compound AVR118 in the treatment of cachexia-related symptoms in cancer patients. The trial will be run at the McGill University Health Centre (MUHC) in Montreal, Quebec. MUHC is one of the most comprehensive academic health centers in North America, representing five teaching hospitals affiliated with the Faculty of Medicine of McGill University.
This study will enroll a minimum of 14 patients who have cancer and show signs of cachexia, which is a syndrome consisting of pronounced muscle wasting, anorexia (appetite loss), and severe fatigue. Dr. Martin Chasen, a medical oncologist / palliative care physician and Clinical Director of the McGill Cancer Nutrition and Rehabilitation Program at McGill University, has been named Principal Investigator. Also included in the team is Professor Neil MacDonald, a well-recognized expert in the field. Pending the outcome of the first 14 patients, there is a provision to increase enrollment to 32 patients or more.
According to Chasen, "as a palliative care oncologist I am excited to be involved in a potential new form of treatment for the debilitating effects of cancer and the side effects of the drugs used to treat it. While there have been tremendous efforts to develop anti-cancer drugs, there has been paucity in the development of new drugs to treat the symptoms associated with this disease."
"We are fortunate to have the opportunity to work with the internationally renowned team of investigators at McGill," said Stephen M. Elliston, President and Chief Executive Officer of ADVR. "Their reputation in palliative care research is recognized by medical oncologists throughout the world," added Elliston. |
